Roivant Sciences Reports Q4 GAAP EPS of $0.28 Beats Estimates but Revenue Misses
Roivant Sciences reported a better-than-expected GAAP earnings per share (EPS) for the fourth quarter, though revenue fell short of estimates and declined significantly year-over-year. The company also disclosed strong cash reserves as of March 31, 2026.
Tickers: $ROIV
Topics: Earnings Financial Performance